![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.60 | 19.75 | 20.60 | - | 3,607 | 08:00:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -500.00 | 89.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/4/2021 15:25 | Yes I saw that, alarming .... its been very weak for a while I am not sure what has caused that. It was bumbling along on low volume and then fell off the radar. Very weird. Looks like its an error somewhere as the price is just recovering..... volumes have been low. | ![]() fse | |
05/4/2021 15:20 | BVC never ceases to surprise me - -25% on TASE today. | ![]() picsous | |
02/4/2021 10:30 | Yes, loads of improvements, ready for the split up? | ![]() wizzkid211 | |
02/4/2021 09:48 | They seem to have done a lot of branding/website improvements on all the companies. | ![]() paulisi | |
01/4/2021 20:20 | Ador/Adaltis linked companies. | ![]() fse | |
31/3/2021 20:31 | Reposted here. Well worth looking at and gives a better idea as to the current scope of this company. Doc... try TT instead of xx... cheers Heres a link to NFVTime and UCPE management. | ![]() fse | |
31/3/2021 17:43 | hxxps://www.telco.co New website looks swish and hopefully sign of more aggressive marketing approach | ![]() doccash | |
29/3/2021 16:35 | The TB test. Heres a recap of the very recently announced Covid saliva test The group has commenced taking orders and expects to begin delivering the kit in April. This new kit, which is part of Adaltis’ MOLgen product range, consists of reagents that have been developed to detect SARS-CoV-2 in saliva samples that are collected by an individual chewing a cotton ball for 30 seconds and then spitting it (or spitting directly) into a small plastic collector tube (a Salivette). It uses the RT-PCR technique, which ensures the highest levels of diagnostic accuracy compared with other saliva-based tests currently available in the market that primarily use the lateral flow method, which are far less accurate causing many false negatives and positives. | ![]() fse | |
29/3/2021 11:21 | [...] Remember BATM were part of Israeli mission to India last year donating equipment including ventilators so probably good relationship established | ![]() doccash | |
29/3/2021 10:59 | Agreed - the new lab testing equipment had a lot of interest in European hospitals.This has created an opportunity to open the Indian market. | ![]() paulisi | |
29/3/2021 09:53 | I believe this is consolidating their reputation as a serious global diagnostic company. Only at study stage and sales next year so unlikely to move price. However this is another offer to the markets to reconsider the company as a serious player. | ![]() doccash | |
29/3/2021 08:26 | No volume this morning, thus no price impact. | ![]() paulisi | |
29/3/2021 07:43 | Just to add to the post of wizzkid211 | ![]() james dean | |
29/3/2021 07:30 | Tuberculosis in India From Wikipedia, the free encyclopedia Jump to navigationJump to search tuberculosis patient Tuberculosis in India is includes all experience, culture, and health response which India has with the disease tuberculosis. Tuberculosis in India is a major health problem causing about 220,000 deaths every year. The cost of the death and disease in the Indian economy between 2006 and 2014 was approximately USD 1 billion.[1] Despite the historical challenges, the technology and health care for treating tuberculosis have improved. In 2020 the Indian government made bold statements to eliminate TB from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating TB. MASSIVE market just in INDIA!!! India bears a disproportionately large burden of the world's tuberculosis rates, as it continues to be the biggest health problem in India. India is the highest TB burden country with World Health Organization (WHO) statistics for 2011 giving an estimated incidence figure of 2.2 million cases of TB for India out of a global incidence of 9.6 million cases.[2] Tuberculosis is India's biggest health issue, but what makes this issue worse is the recently discovered phenomenon of TDR-TB - Totally Drug-Resistant Tuberculosis. This issue of drug-resistant TB began with MDR-TB, and moved on to XDR-TB. Gradually, the most dangerous form has situated itself in India as TDR-TB. | ![]() wizzkid211 | |
29/3/2021 07:11 | More markets to sell the new diagnostic machine. | ![]() paulisi | |
29/3/2021 07:08 | They are becoming an impressive medical diagnostic outfit, and this will be excellent publicity for what they have the cability to do | ![]() doccash | |
29/3/2021 07:02 | BATM Advanced Communications Ld BATM develops molecular diagnostics test for TB | ![]() wizzkid211 | |
28/3/2021 19:59 | Just some info on virolens for those interested | ![]() doccash | |
28/3/2021 19:53 | TT Electronics plc ("TT") notes today's rise in the share price and provides an update on evaluation trials in the UK of Virolens(R), a rapid COVID-19 screening device for which TT is the exclusive manufacturing partner. TT understands that the Medicines and Healthcare products Regulatory Authority ("MHRA"), which is responsible for ensuring that medical devices meet applicable standards of safety, quality and efficacy, is in the final stages of registering Virolens for use and sale in Great Britain. Revenues to TT from the sale of Virolens following final MHRA registration would be dependent on iAbra's potential end customers in Great Britain converting expressions of interest into firm orders. A high proportion of the commercial interest in Virolens to date has been outside of Great Britain and any revenues resulting from this interest require further regulatory approvals in those territories. There continues to be a wide range of potential commercial outcomes and hence no certainty as to the financial impact on TT. | ![]() doccash | |
28/3/2021 14:20 | Virolens is very dubious! Check out the reports | ![]() krutt | |
27/3/2021 10:32 | Apologies - Heathrow testing this 20s lateral test. | ![]() paulisi | |
26/3/2021 22:50 | I can't recall BATM in for a contract at Heathrow. Most interest and sales are in Europe.The world is a massive market with massive opportunities for Covid and respiratory pathogen testing in a variety of settings. | ![]() doccash | |
26/3/2021 22:24 | Yes you are. The saliva test is more about detecting variants and levels of antibodies. Just look at the specifics. In any event there is plenty of demand here to support numerous companies | ![]() fse | |
26/3/2021 22:16 | Am i?BATM targeting airports and large sporting events and so is this 98% lateral test that produces results in 20s.Heathrow are testing it. | ![]() paulisi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions